The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1326
Aliskiren/Valsartan (Valturna) for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the use of aliskiren (Tekturna), a direct renin inhibitor, with valsartan (Diovan), an angiotensin-receptor blocker (ARB), in a fixed-dose combination as Valturna (Novartis) for treatment of hypertension in patients already taking both drugs or not adequately controlled on monotherapy, and as initial therapy in those likely to need multiple drugs to control their blood pressure.

MECHANISM OF ACTION — Aliskiren and valsartan block the renin-angiotensin-aldosterone system (RAAS) at different points. Renin cleaves angiotensinogen to form angiotensin I, which is converted to angiotensin II. This raises blood pressure, leading to a decrease in renin secretion by the kidney. Valsartan blocks binding of angiotensin II to the AT1 receptor, which lowers blood pressure and increases plasma renin activity. Aliskiren binds to the catalytic site of renin, inhibiting formation of angiotensin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aliskiren Valsartan (Valturna) for Hypertension
Article code: 1326b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian